The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing tumors.
Guidelines | Ovarian Cancer Guideline Updates 2024
Ovarian Cancer Guideline Updates 2024
Articles
Videos
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5